Firma QIAGEN N.V., Autor bei PR-Web

QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

Posted on 15. April 2019 by Firma QIAGEN N.V. Posted in Research / Development Tagged bladder, cancer, fgfr, market, ngs, patients, qiagen, qiagen's, qiasymphony, rgq, statements, therascreen, urothelial, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, […]

QIAGEN receives approval for EGFR test in lung cancer as companion diagnostic in Japan

Posted on 17. January 2019 by Firma QIAGEN N.V. Posted in General Tagged cancer, egfr, market, ngs, nsclc, patients, pmda, qiagen, qiagen's, qiasymphony, rgq, statements, therascreen, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the therascreen® EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s VIZIMPRO® (dacomitinib) for EGFR […]

QIAGEN acquires N-of-One, expanding its clinical bioinformatics capabilities in molecular oncology decision support

Posted on 7. January 2019 by Firma QIAGEN N.V. Posted in Research / Development Tagged cancer, currency, market, new, ngs, patients, qci, qiagen, qiagen's, rwe, securities, sequencing, statements, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of […]

QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB

Posted on 7. January 2019 by Firma QIAGEN N.V. Posted in Research / Development Tagged bcg, dot, hiv, market, patients, qft, qiagen, qiagen's, quantiferon, quantum, securities, statements, vaccines, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB. The […]

QIAGEN partners with U.K. to expand biomarker research in Manchester

Posted on 11. July 2018 by Firma QIAGEN N.V. Posted in Research / Development Tagged biomarker, clinical, currency, financial, market, new, nhs, patients, qiagen, qiagen's, securities, social, statements, with

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with multiple organizations to support creating a global genomics campus in Manchester, U.K., for innovation, life sciences, translational science and molecular diagnostics. QIAGEN is working with Health Innovation […]